去甲基化治疗骨髓增生异常综合征临床疗效观察

The Clinical Efficacy of Demethylation Drug on Myelodysplastic Syndrome

目的回顾性分析地西他滨联合低剂量HAG方案和单用HAG方案治疗骨髓增生综合征(MDS)的临床疗效和安全性。方法所有患者按其治疗方案分组,联合组应用地西他滨联合低剂量HAG化疗,HAG组应用最佳剂量化疗;比较两组患者的治疗有效率、生存期及不良反应。结果联合治疗组的有效率显著高于HAG组(P<0.05),无病生存期显著长于HAG组(P<0.05),两组总体生存期无明显差异(P>0.05),联合治疗组的不良反应率明显低于HAG组(P<0.05)。结论使用地西他滨联合低剂量HAG化疗后患者的临床疗效显著、无病生存期较长,不良反应率明显下降。

Objective To retrospectively explore the clinical efficacy and adverse reactions of decitabine combined with low-dose HAG chemotherapy and HAG chemotherapy. Methods All patients were divided into two groups according to their chemotherapy. The combined treatment group was treated with low-dose chemotherapy combined with decitahine. The chemotherapy group was treated with the best dose. Total effective rate,survival time and adverse re- actions were compared between the two groups. Results The total effective rate, disease free survival in combined treat- ment group were significantly higher than the chemotherapy group （ P 〈 0.05 ）. The overall survival had no obvious differ- ent（ P 〉 0.05）. The adverse reactions in combined treatment group were significantly lower than in the chemotherapy group（P 〈 0.05）. Conclusion Decitabinecombined with low-dose HAG scheme in treating myelodysplastic syndrome has obvious effect, long disease free survival time and lower adverse reactions.